Peter Kenyon

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

PRICING AND THE INVESTMENT DECISION

G. C. Harcourt, Peter Kenyon · Kyklos · 1976 · 143 citations

Investment Strategy, Economics, Asset Pricing +6

A Time Series Analysis of Labour Absence in Australia

Peter Kenyon, Peter Dawkins · The Review of Economics and Statistics · 1989 · 56 citations

Productivity, Economics, Affect Labor Absence +13

Phase II Trial of Alfimeprase, a Novel-Acting Fibrin Degradation Agent, for Occluded Central Venous Access Devices

Stephan Moll, Peter Kenyon, Luigi F. Bertoli et al. · Journal of Clinical Oncology · 2006 · 52 citations · Full text

Small Town Renewal: Overview and Case Studies.

Peter Kenyon, Alan Black · 2001 · 37 citations

Urban Geography, Urban Policy, Community Development +5